ALX Oncology Added to Russell 2000® and 3000® Indexes
17 Settembre 2020 - 1:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that it will be
added as a member of the Russell 2000® and 3000® Indexes, effective
after the U.S. market opens tomorrow, September 18, 2020, as a part
of Russell’s quarterly additions of select initial public offering
(“IPO”) companies.
“We are pleased to join the Russell Indexes within just two
months of our IPO,” said Peter Garcia, Chief Financial Officer of
ALX Oncology. “Our inclusion validates the potential we believe
investors see in ALX Oncology and will further increase the overall
awareness and visibility of our stock within the investment
community.”
The Russell U.S. indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s U.S. indexes. Russell indexes are
part of FTSE Russell, a leading global index provider.
About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company focused
on helping patients fight cancer by developing therapies that block
the CD47 checkpoint pathway and bridge the innate and adaptive
immune system. ALX Oncology’s lead product candidate, ALX148, is a
next generation CD47 blocking therapeutic that combines a
high-affinity CD47 binding domain with an inactivated, proprietary
Fc domain. ALX148 has demonstrated promising clinical responses
across a range of hematologic and solid malignancies in combination
with a number of leading anti-cancer agents. ALX Oncology intends
to advance ALX148 into clinical development for the treatment of
myelodysplastic syndromes and to continue clinical development for
the treatment of a range of solid tumor indications. For more
information, please visit ALX Oncology’s website at
https://www.alxoncology.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on ALX
Oncology’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause ALX Oncology’s actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. These
statements include but are not limited to statements regarding
investor awareness of ALX Oncology’s stock. These and other risks
are described more fully in ALX Oncology’s filings with the
Securities and Exchange Commission (“SEC”), including ALX
Oncology’s Quarterly Report on Form 10-Q, filed with the SEC on
August 27, 2020, and other documents that ALX Oncology subsequently
files with the SEC from time to time. Except to the extent required
by law, ALX Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alx@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2023 a Lug 2024